Treats obsessions and compulsions. ANDA 75900, held by Chartwell Rx. Fluvoxamine Maleate.
As of Nov 16, 2026, ANDA 75900 (Fluvoxamine Maleate), held by Chartwell Rx, was first approved by FDA on Feb 23, 2006, with 6 approved supplements and 0 published complete response letters.
Fluvoxamine maleate tablets are indicated for the treatment of obsessions and compulsions in patients with obsessive compulsive disorder (OCD). 1.1 Obsessive-Compulsive Disorder
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 23, 2006 | Original application | Approved | None posted |
| Fluvoxamine Maleate25MG · tablet;oral | Fluvoxamine Maleate | Discontinued |
| Fluvoxamine Maleate50MG · tablet;oral | Fluvoxamine Maleate | Discontinued |
| Fluvoxamine Maleate100MG · tablet;oral | Fluvoxamine Maleate | Discontinued |
| Mar 13, 2025 | Supplement 14Labeling · Standard review | Approved | None posted |
| Apr 15, 2009 | Supplement 10Labeling | Approved | None posted |
| Feb 27, 2009 | Supplement 9Labeling | Approved | None posted |
| Oct 16, 2007 | Supplement 7Labeling | Approved | None posted |
| Jul 9, 2007 | Supplement 6Labeling | Approved | None posted |
| Oct 18, 2006 | Supplement 4Labeling | Approved | None posted |
| Feb 23, 2006 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters